1,721,079 research outputs found
Root and crown tot of olive caused dy Phytophthora spp.
Full text linkPhytophthora root and crown rot has been traditionally considered a minor disease of olive. However, in recent years it has
been recognized as an emerging problem in several olive-growing countries such as Australia, Italy and Spain probably as a
consequence of the expansion of plantings in new areas with heavy soils and the more intensive use of irrigation in both olive nurseries and commercial groves. The disease has been reported from most olive-growing countries and is caused by several soil -borne species of Phytophthora, including P. cinnamomi, P. citricola, P. cryptogea,
P. drechsleri, P. gonapodyides, P. inundata, P. megasperma,P. nicotianae and P.palmivora. Diagnosis is currently based on the
isolation and identification of isolates by both traditional and molecular methods. New molecular techniques are currently available that could be applied for both the identification of isolates and Phytophthora infections directly in host-tissues as well as insoil and water samples. A number of dedicated databases could improve the efficiency of these techniques. Moreover, DNA analysis has greatly contributed to phylogenetic studies of Phytophthora. Control of Phytophthora root and crown rot of olive is mainly based on preventive measures
Immunosupressive treatment (IS) of idiopathic nephrotic syndrome (NS) with Prednisone (PDN) and cyclophosphamide
No full text
Acute hepatitis with bridging necrosis due to hydralazine intake. Report of a case
No full textA 59-year-old woman was admitted to the hospital for evaluation of her hypertension. She was treated with hydralazine; two days later a severe acute hepatitis supervened. On discontinuation of the agent, the liver damage disappeared, relapsed during inadvertent rechallenge, and healed following permanent withdrawal from the drug. Histologic study of the liver showed severe acute hepatitis with bridging necrosis (so-called subacute hepatitis). Six months after discontinuation of hydralazine, a second liver biopsy specimen showed a complete remission of the disease. This hydralazine-induced hepatitis appears to be fully reversible and to differ both on clinical and histological grounds from two previous reports documenting a granulomatous liver disease
Immunosoppressive treatment for idiopathic nephrotic syndrome with corticosteroids and cyclophosphamide
No full textIMMUNOSUPPRESSIVE TREATMENT OF MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS
No full textThe treatment of membranoproliferative glomerulonephritis (MPGN) is considered by most authors as unrewarding, and the disease progresses to end-stage renal disease (ESRD). We studied the effectiveness of a new immunosuppressive (IS) regimen by analyzing the rates of remission, relapse and progression to ESRD in 19 patients with MPGN. The treatment consisted of 4 phases: (1) induction with intravenous boluses of methylprednisolone plus cyclophosphamide (CPM) orally; (2) maintenance with oral prednisone (PDN) in an alternateday regimen and CPM in a daily oral dose; (3)tapering during which PDN alone was slowly decreased; (4) discontinuation when CPM was omitted and PDN slowly withdrawn according to the steroid withdrawal schedule. At the end of the treatment that lasted on average 10 +/- 1 months, 15 patients remitted, 3 improved and 1 progressed. There were 8 relapses in 6 patients: 4 in 3 patients were treated with repeat cycles and remitted completely. Four patients who had relapsed after 4, 8, 11 and 13 years of remission refused retreatment and progressed rapidly to ESRD. All patients treated and retreated after relapsing had remissions, while renal failure and disease progression occurred in 1 patient only. Plasma creatinine averaged, in the whole group, 165 +/- 26 before, 156 +/- 30 after treatment and 224 +/- 57 mu M/l at the end of 7.4 +/- 0.8 years of follow-up. An intensive IS regimen combining steroids and alkylating agents in high doses and for a prolonged time is effective in inducing remission and halting progression to ESRD in patients with MPGN
- …
